Rigel to Participate at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial offer of Rigel, will participate at two investor conferences in November. Details of the events are as follows:

(Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)

2011 Credit Suisse Annual Health Care ConferenceDate: Thursday, November 10 at 1:00p.m. MSTLocation: Phoenix, AZSpeaker: James M. Gower

23rd Annual Piper Jaffray Health Care ConferenceDate: Wednesday, November 30 at 12:00 p.m. ESTLocation: New York, NYSpeaker: Ryan Maynard

Both events will be webcast live and can be accessed at www.rigel.com.  Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 trials for asthma.

Contact: Ryan MaynardPhone: 650.624.1284Email: [email protected]

SOURCE Rigel Pharmaceuticals, Inc.